Company Overview and News


Add QGEN
to your dashboard

Headline News

Weak Earnings Growth Drops Qiagen NV (QGEN) to Hold

2017-11-16 investorplace
With a $7.2 billion market value, Qiagen NV (NASDAQ:QGEN) ranks in the top half of its industry group, Life Sciences Tools & Services, and in the top 25% of its sector group, Health Care, in market value. From the prospective of investment attractiveness, The current Portfolio Grader ranking for QGEN puts it 23 among the 33 companies in this industry group, giving it a below-average spot; in the third quartile of the sector with a ranking of 453 among the 782 companies in the sector, and number 2,909 in the nearly 5,000 company Portfolio Grader universe. (2-0)

Corporate News Blog - Myriad Teams Up with Department of Veterans Affairs for Clinical Trials to Evaluate the Effectiveness of GeneSight(R) Test in Improving MDD In Veterans

2017-11-13 accesswire
LONDON, UK / ACCESSWIRE / November 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Myriad Genetics, Inc. (NASDAQ: MYGN), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=MYGN. The Company's wholly-owned subsidiary, Assurex Health, announced on November 10, 2017, that it has teamed up with the Department of Veterans Affairs (VA) and launched a nationwide, multi-center clinical trial to evaluate the effectiveness of its GeneSight® test. (19-0)

QIAGEN (QGEN) Faces Declining HPV Sales, Intense Competition

2017-11-10 zacks
On Nov 9, we issued an updated research report on QIAGEN N.V. (QGEN - Free Report) . The stock currently carries a Zacks Rank #4 (Sell). (10-0)

Rating for Qiagen NV (QGEN) Drops….. Weak Industry Group Rank

2017-11-09 investorplace
Qiagen NV (NASDAQ:QGEN) is one of 33 companies within the Life Sciences Tools & Services GICS industry group, which is in turn part of the 785 company GICS Health Care sector. QGEN has a market value of $7.7 billion which is in the top half of its industry group. The ranking for QGEN by Portfolio Grader places it 21 among the 33 companies in this industry group, giving it a lower than average position; in the top half of the sector with a ranking of 338 among the 785 companies in the sector, and number 2,179 in the nearly 5,000 company Portfolio Grader universe. (2-0)

HTGM / HTG Molecular Diagnostics, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2017-11-08 fintel.io
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) has 23 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,694,329 shares. Largest shareholders include Qiagen Nv, Glaxosmithkline Plc, FMR LLC / Fidelity Management & Research, Cormorant Asset Management, LLC, and Vanguard Group Inc. (34-1)

QIAGEN NV (QGEN) Q3 2017 Results - Earnings Call Transcript

2017-11-07 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome, and thank you for joining QIAGEN's Conference to discuss the Third Quarter 2017 Results. At this time, all participants are in listen-only mode. Please be advised that this call is being recorded at QIAGEN's request and will be available on their website. The presentation will be followed by a question-and-answer session. (130-0)

QIAGEN (QGEN) Meets Q3 Earnings, Lags Revenues, Keeps View

2017-11-07 zacks
QIAGEN N.V. (QGEN - Free Report) reported third-quarter 2017 adjusted earnings per share of 32 cents, up 10.3% year over year. The reported figure is on par with the Zacks Consensus Estimate. (5-0)

Robust Quant Score Keeps Qiagen NV (QGEN) a Buy

2017-11-02 investorplace
Qiagen NV (NASDAQ:QGEN) is ranked as a Buy using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing methodology. QGEN has recently seen its Portfolio Grader rating upgraded from a Hold to a Buy. (2-0)

Can Molecular Diagnostics Drive Hologic's (HOLX) Q4 Earnings?

2017-11-01 zacks
Hologic, Inc. (HOLX - Free Report) is slated to report fourth-quarter fiscal 2017 financial results on Nov 8, after the closing bell. Last quarter, the company delivered a positive earnings surprise of 2%. Notably, Hologic’s earnings surpassed the Zacks Consensus Estimate in all of the past four quarters, the average beat being 4.2%. (10-0)

Healthy Earnings Momentum Keeps Qiagen NV (QGEN) a Buy

2017-10-26 investorplace
Portfolio Grader currently ranks Qiagen NV (NASDAQ:QGEN) a Buy. The methodology for investing incorporated in this analytical tool developed by Louis Navellier assesses and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. QGEN has recently seen its Portfolio Grader rating upgraded from a Hold to a Buy. (2-0)

Analytics for Quant Score Drive Upgrade of Qiagen NV (QGEN) to Buy

2017-10-19 investorplace
Qiagen NV (NASDAQ:QGEN) is a component of the 33 company Life Sciences Tools & Services GICS industry group, which is a segment of the 783 company GICS Health Care sector. The market value of QGEN is $7.9 billion which falls in the top quarter of its industry group. Portfolio Grader's current ranking for QGEN puts it 13 among the 33 companies in this industry group, giving it an above-average position; in the top quartile of the sector with a ranking of 175 among the 783 companies in the sector, and number 1,279 in the nearly 5,000 company Portfolio Grader universe. (2-0)

Henry Schein Gains on Strategic Buyouts, Cost Concern a Woe

2017-10-13 zacks
On Oct 13, we issued an updated research report on Henry Schein, Inc. (HSIC - Free Report) , a leading distributor of health care products and services across the globe. The company carries a Zacks Rank #3 (Hold). (87-0)

NuVasive's (NUVA) PRECICE System Gets Expanded FDA Approval

2017-10-13 zacks
NuVasive, Inc. (NUVA - Free Report) has been in the news of late for the receipt of expanded FDA 510(k) approval for its advanced magnetic and non-invasive limb lengthening technology — PRECICE. (90-0)

Bruker (BRKR) at a 52-Week High: What's Driving the Stock?

2017-10-13 zacks
Bruker Corporation (BRKR - Free Report) scaled a new 52-week high of $30.93 on Oct 12, eventually closing a bit lower at $30.71. This Zacks Rank #3 (Hold) stock has a market cap of $4.88 billion. (93-0)

Abbott Banks on FDA Approvals and Buyouts, Competition Rife

2017-10-13 zacks
On Oct 12, we issued an updated research report on Abbott (ABT - Free Report) — a global healthcare company dedicated toward improving life through the development of products and technologies. The stock carries a Zacks Rank #3 (Hold). (83-0)

CUSIP: N72482107